Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab - PubMed
5 hours ago
- #Biomarker
- #Immunotherapy
- #Hepatocellular Carcinoma
- Plasma GPC3 levels correlate with tumor GPC3 expression in hepatocellular carcinoma (HCC).
- High plasma GPC3 (>10 pg/ml) is associated with worse clinical outcomes, including shorter progression-free and overall survival.
- Plasma GPC3 was a better predictor of 6- and 12-month outcomes compared to tumor-based measures.
- The study suggests plasma GPC3 as a non-invasive biomarker for HCC, particularly in patients treated with atezolizumab plus bevacizumab.
- Discrepancies between plasma and tumor GPC3 levels were noted, indicating potential complementary roles in assessment.